DA Davidson reiterated their buy rating on shares of Phreesia (NYSE:PHR – Free Report) in a report published on Thursday, Marketbeat.com reports. They currently have a $32.00 price target on the stock.
Several other equities research analysts also recently commented on the company. JMP Securities reiterated a market outperform rating and issued a $30.00 price objective on shares of Phreesia in a report on Friday, August 30th. Stephens restated an overweight rating and set a $28.00 price objective on shares of Phreesia in a research report on Friday, May 31st. Truist Financial reissued a buy rating and issued a $29.00 target price on shares of Phreesia in a report on Monday, July 1st. Canaccord Genuity Group cut their target price on shares of Phreesia from $37.00 to $34.00 and set a buy rating for the company in a report on Friday, May 31st. Finally, Needham & Company LLC reissued a buy rating and set a $29.00 target price on shares of Phreesia in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $30.42.
View Our Latest Analysis on PHR
Phreesia Stock Down 8.3 %
Insider Transactions at Phreesia
In other news, General Counsel Allison C. Hoffman sold 14,110 shares of Phreesia stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $26.03, for a total value of $367,283.30. Following the transaction, the general counsel now owns 121,003 shares of the company’s stock, valued at approximately $3,149,708.09. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, General Counsel Allison C. Hoffman sold 14,110 shares of Phreesia stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $26.03, for a total value of $367,283.30. Following the completion of the sale, the general counsel now directly owns 121,003 shares in the company, valued at approximately $3,149,708.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Evan Roberts sold 1,669 shares of the stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $23.74, for a total value of $39,622.06. Following the completion of the transaction, the chief operating officer now directly owns 753,234 shares in the company, valued at $17,881,775.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,337 shares of company stock valued at $736,750. Company insiders own 5.80% of the company’s stock.
Hedge Funds Weigh In On Phreesia
Several large investors have recently made changes to their positions in PHR. Capital International Investors raised its holdings in Phreesia by 221.1% in the 1st quarter. Capital International Investors now owns 2,593,063 shares of the company’s stock worth $62,052,000 after purchasing an additional 1,785,463 shares during the period. Champlain Investment Partners LLC purchased a new position in Phreesia during the first quarter valued at $29,941,000. Brown Advisory Inc. grew its position in shares of Phreesia by 22.2% in the fourth quarter. Brown Advisory Inc. now owns 3,950,356 shares of the company’s stock valued at $91,451,000 after purchasing an additional 716,374 shares during the period. Norges Bank purchased a new stake in shares of Phreesia during the fourth quarter worth about $8,199,000. Finally, Blair William & Co. IL raised its position in shares of Phreesia by 42.6% during the 1st quarter. Blair William & Co. IL now owns 752,700 shares of the company’s stock worth $18,012,000 after purchasing an additional 224,950 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Articles
- Five stocks we like better than Phreesia
- The 3 Best Blue-Chip Stocks to Buy Now
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- How Can Investors Benefit From After-Hours Trading
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- The 3 Best Retail Stocks to Shop for in August
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.